This paper is the 28th consecutive installment of the annual review of research concerning
the endogenous opioid system, now spanning over a quarter-century of research. It …

In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …

Non-invasive brain stimulation therapy for autism spectrum disorder (ASD) has shown
beneficial effects. Recently, we and others demonstrated that visual sensory stimulation …

Several useful animal models for parkinsonism have been developed so far. Haloperidol‐
induced catalepsy is often used as a rodent model for the study of motor impairments …

G‐protein‐coupled receptors (GPCR s) are the largest family of integral membrane
receptors with key roles in regulating signaling pathways targeted by therapeutics, but are …

Repetitive behaviors are diagnostic for autism and common in related neurodevelopmental
disorders. Despite their clinical importance, underlying mechanisms associated with the …

Adenosine A2A receptors are highly concentrated in the striatum, where they play an
important modulatory role of glutamatergic transmission to the GABAergic enkephalinergic …

Evidence obtained in rodent and primate models of Parkinson's disease (PD) and
preliminary clinical trials, indicates that adenosine A2A receptor antagonists might represent …

Adenosine A1 and A2A receptors are colocalized with dopamine D1 and D2 receptors on
striatal projection neurons and adenosine antagonists have been proposed as adjunctive …

The influence of the selective adenosine A2A receptor antagonist ZM 241385 on exogenous
l-DOPA-derived dopamine (DA) release in intact and dopamine-denervated rats was studied …